The 10-second takeaway
For the quarter ended Dec. 31 (Q4), GenMark Diagnostics crushed expectations on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly. GAAP loss per share contracted.
Margins expanded across the board.
GenMark Diagnostics reported revenue of $9.4 million. The five analysts polled by S&P Capital IQ foresaw sales of $7.1 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $2.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.15. The four earnings estimates compiled by S&P Capital IQ anticipated -$0.21 per share. GAAP EPS were -$0.15 for Q4 compared to -$0.27 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 49.6%, much better than the prior-year quarter. Operating margin was -48.7%, much better than the prior-year quarter. Net margin was -49.7%, much better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $10.3 million. On the bottom line, the average EPS estimate is -$0.15.
Next year's average estimate for revenue is $35.4 million. The average EPS estimate is -$0.76.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with nine members out of 12 rating the stock outperform, and three members rating it underperform. Among six CAPS All-Star picks (recommendations by the highest-ranked CAPS members), four give GenMark Diagnostics a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on GenMark Diagnostics is outperform, with an average price target of $11.13.
Is GenMark Diagnostics the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add GenMark Diagnostics to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.